基本信息:
- 专利标题： NOVEL COMPOUNDS AS JNK KINASE INHIBITORS
- 专利标题（中）：新型化合物作为JNK激酶抑制剂
- 申请号：PCT/US2014/068333 申请日：2014-12-03
- 公开(公告)号：WO2015084936A1 公开(公告)日：2015-06-11
- 发明人： FENG, Yangbo , LOGRASSO, Philip , ZHENG, Ke , PARK, Chul Min
- 申请人： THE SCRIPPS RESEARCH INSTITUTE , FENG, Yangbo , LOGRASSO, Philip , ZHENG, Ke , PARK, Chul Min
- 申请人地址： 10550 North Torrey Pines Road La Jolla, California 92037 US
- 专利权人： THE SCRIPPS RESEARCH INSTITUTE,FENG, Yangbo,LOGRASSO, Philip,ZHENG, Ke,PARK, Chul Min
- 当前专利权人： THE SCRIPPS RESEARCH INSTITUTE,FENG, Yangbo,LOGRASSO, Philip,ZHENG, Ke,PARK, Chul Min
- 当前专利权人地址： 10550 North Torrey Pines Road La Jolla, California 92037 US
- 代理机构： PERDOK, Monique M. et al.
- 优先权： US61/911,741 20131204; US62/001,872 20140522
- 主分类号： A01N43/56
- IPC分类号： A01N43/56
摘要：
The present invention is directed to modulators, such as inhibitors, of JNK isoform 2 (JNK2) or isoform 3 (JNK3) comprising compounds of formula (I) or formula (II) as described herein. Compounds of the invention can be used for treatment of a medical disorder in a patient wherein modulation of JNK3 is medically indicated, such as when the disorder is Parkinsons disease (PD) Alzheimer's disease (AD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), myocardial infarction (MI), glaucoma, obesity, diabetes, cancer, rheumatoid arthritis, fibrotic disease, pulmonary fibrosis, kidney disease, liver inflammation, Crohns disease, hearing loss, Prader Willi syndrome, or a condition where modification of feeding behavior is medically indicated.
摘要（中）：
本发明涉及包含本文所述的式（I）或式（II）化合物的JNK同种型2（JNK2）或同种型3（JNK3）的调节剂，例如抑制剂。 本发明的化合物可用于治疗患有医学上指示JNK3调节的患者的医学病症，例如当疾病是帕金森病（PD）阿尔茨海默病（AD），亨廷顿病（HD），肌萎缩性侧索硬化症 （ALS），多发性硬化症（MS），心肌梗塞（MI），青光眼，肥胖症，糖尿病，癌症，类风湿性关节炎，纤维化疾病，肺纤维化，肾脏疾病，肝脏炎症，克罗恩病，听力损失，Prader Willi综合征或 在医疗上指示进食行为改变的条件。